Your next growth vector isn't a new patient

The FDA's Pharmacy Compounding Advisory Committee meets July 23 and 24 to consider adding seven peptides to the 503A bulk list, which decides what compounding pharmacies can legally make.

RFK Jr. has signaled looser peptide restrictions, and Hims, which bought a California peptide facility last year, moved on the news. The whole category is hunting for what grows revenue after GLP-1.

Worth saying plainly: for now, the clinical evidence that most of these peptides do much in humans is still thin. A gold rush built on weak evidence is a retention problem waiting to happen.

Amazon and others are pushing agentic AI past admin work into triage and patient-facing workflows. One health system running 3.2 million interactions a year shifted 630 hours of labor a week from verification to actual patient help.

For telehealth, the obvious use is cost: fewer support hours, faster intake.

The higher-value use is retention. The same agent that triages a ticket can flag an at-risk patient and trigger the right touch. Most brands will only use the cost half.

Virtual care is heading into a sixth straight year of reimbursement limbo, with policy still unsettled across Medicare, Medicaid, and commercial payers.

Encounters are up 79% since 2019, but the money to pay for them has not kept pace, and health systems are absorbing the gap.

For DTC telehealth this is the quiet case for owned retention. When reimbursement is shaky, the revenue you control, the patients who stay and re-buy, is the revenue you can count on.

While the whole industry hunts the next molecule, the cheapest growth is sitting in your patient list.

The peptide scramble is the same instinct that drove the GLP-1 boom. Find a new product, run new ads, acquire new patients.

But new acquisition is the most expensive growth there is. And telehealth punishes it hardest, with long decision cycles, compliance gates, and CPMs that climb every year.

At scale, telehealth CAC payback runs 3-5+ months. Every new patient is months of spend before a dollar of profit.

Expansion revenue, an existing patient buying more, staying longer, or adding a treatment, carries almost no acquisition cost. You already paid to get them.

So the brand chasing peptides for fresh signups is reaching for the expensive lever while the cheap one sits untouched in the CRM.

This is where most brands break it. They bolt an e-commerce upsell onto a medical relationship and wonder why trust drops.

The cross-sell that works reads as provider guidance, not a cart prompt:

And it is signal-triggered, not blasted. The day-45 patient with visible results is ready for the next step. A universal blast on day 1 burns the credibility you need.

The instinct is to sell a second product. Frequently the bigger lever is selling more of the first one.

Locking a GLP-1 patient into a 3 to 6 month plan usually drives more lifetime value than adding a complementary treatment, and multi-month plans already retain 2 to 3 times better than monthly.

Run both. Just do not assume the cross-sell is the bigger number. For most telehealth books, the plan-length upgrade is.

Built together, signal-triggered cross-sell and multi-month upgrades are a big part of why a healthy lifecycle program lands at 15 to 25% of revenue instead of single digits.

The takeaway. The next growth vector probably is not a new molecule the FDA is still arguing about. It is the patient you acquired last quarter, given a clinically-framed reason to go deeper or stay longer. Build that before you chase the peptide.

If peptides clear the FDA and you add them, remember what thin clinical evidence means for retention: patients who do not feel a result leave fast, and they tell people.

The brands that win a weak-evidence category set honest expectations up front and retain on experience. Sell it like a miracle and you build a refund queue instead.

Everyone is aiming agentic AI at cost: deflect tickets, speed up intake. Fine.

The bigger return is pointing it at churn. Flag the patient who skipped a refill or went quiet at day 60, and trigger the right message before they cancel. Cost savings are linear. A saved patient compounds.

Pick one signal and build one clinically-framed expansion touch around it.

Take your patients at roughly day 45 on treatment, the point where results start to show and trust is highest.

Write one message in your provider's voice offering the genuinely relevant next step: a multi-month plan that improves outcomes, or one adjacent treatment patients at that stage actually benefit from.

Frame it as clinical guidance, never as a cart upsell.

You are not adding a campaign. You are turning one trust moment you already have into expansion revenue you are currently leaving on the table.

If retention is your biggest revenue leak, that’s what we fix. growthtrigger.xyz

Reply to this with your biggest retention challenge. I read and respond to every single one.